
Low-dose aspirin could help decrease the risk of developing cancer by 25 percent, says study.
The findings of the study suggest that a low-dose pill can be taken to help keep cancer at bay, in the same way that aspirin is currently prescribed to protect against heart disease, the Daily Express reported.
Advertisement
Experts at Queen's University, Belfast, used information from the National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer trial for a large scale investigation of the effect of aspirin and ibuprofen on head and neck cancer risk.
They found that people were 22 percent more likely to avoid developing head and neck cancers if they took aspirin on a weekly and monthly basis.
The medicine pill, dubbed "wonderdrug," was most effective in throat cancer prevention.
For those aged 55-74, there was a "significant" reduction of head and neck cancer risk between weekly and monthly aspirin use.
The study has been published in the British Journal of Cancer.
Source: ANI
Advertisement
The medicine pill, dubbed "wonderdrug," was most effective in throat cancer prevention.
For those aged 55-74, there was a "significant" reduction of head and neck cancer risk between weekly and monthly aspirin use.
The study has been published in the British Journal of Cancer.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News

India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.

Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.

Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.

Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.

Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.